HOME >> MEDICINE >> NEWS
National enforcement program galvanizes action at the state and local levels to reduce teen drinking

rs.

Wolfson, associate professor of public health sciences (social sciences and health policy) and director of the Center for Community Research, said the 13-member Wake Forest team documented a dramatic increase in enforcement activities. "Clearly, the Enforcing Underage Drinking Laws program stimulated activity on a broad scale in the area of underage drinking prevention."

"However, these efforts have not yet produced corresponding changes in alcohol use by youth. While small reductions were observed in the number of youths reporting alcohol use, non-violent consequences of alcohol use, perceptions of alcohol use among peers and attempts to purchase alcohol, there were no statistically significant differences between youth in intervention and comparison communities."

He cautioned that results were based on only one year of intervention "which may not be adequate to affect alcohol use outcomes. Future reports of the national evaluation will include analysis of two years of funding."

He said that despite a uniform national drinking age of 21, "alcohol use by people under 21 is pervasive. Kids drink in large numbers." He said 20 percent of 8th-graders and 50 percent of 12th-graders report they have consumed alcohol in the past 30 days. Such drinking patterns lead to injuries, unsafe sex, and sexual assaults, in addition to the legal consequences.

Wolfson said the Enforcing Underage Drinking Laws program is the first major federal initiative focused exclusively on youth alcohol use. It is funded by the U.S. Office of Juvenile Justice and Delinquency Prevention.

Though the current program is continuing, the Office of Juvenile Justice is planning a new phase that would randomly assign communities to either intervention or controls, employing the use of what are seen as best practices.

"The practices identified by experts as 'best' include conducting regular enforcement actions involving the use of underage decoys who attemp
'"/>

Contact: Robert Conn
rconn@wfubmc.edu
336-716-4587
Wake Forest University Baptist Medical Center
10-Sep-2003


Page: 1 2 3

Related medicine news :

1. National Academies advisory: May 2 Symposium on International Science Policy
2. National Academies News: William H. Foege to receive Public Welfare Medal, Academys highest honor
3. National Academies news: Academy honors 17 for major contributions to science
4. National Academies advisory: Report assesses health implications of perchlorate exposure
5. National Academies Advisory: Jan. 11 public briefing on perchlorate in drinking water
6. National Academies news: Gulf War and Health
7. National survey shows few physicians elected to Congress
8. Six new Roybal Centers for Applied Gerontology established by National Institute on Aging
9. UGA professor receives $3 million grant from National Cancer Institute for breast cancer research
10. National Academies advisory: Nov. 4-6 Frontiers of Science meeting in Irvine, Calif.
11. National Chemistry Week celebrates health and wellness in Washington, D.C., area

Post Your Comments:
(Date:3/30/2015)... March 30, 2015 Mid-America ATTC ... library of medications used in behavioral health and ... iPad and Android—is a convenient, electronic version of ... 1999. The useful resource provides up-to-date information on ... and frequency, side effects, emergency conditions, cautions, considerations ...
(Date:3/30/2015)... Linda, CA (PRWEB) March 30, 2015 ... challenging due to the use of cellular models that ... not the entirety of the disease. , A ... human cells to precise specifications has created ... to develop environmentally and genetically driven in vitro models ...
(Date:3/29/2015)... Calif. (PRWEB) March 30, 2015 Over ... menopause-related symptoms tied to undiagnosed autoimmune, thyroid, or hormone ... thyroid disorders, has personally treated hundreds of patients dealing ... are unaware of the treatment options for their ailments. ... offers solutions to women living with fatigue, brain fog, ...
(Date:3/29/2015)... Telerad RxDx Multispecialty Healthcare Center, ... Accreditation on 11th January 2015. The accreditation from ... Providers) comes as a true recognition of the ... RxDx., With Telerad RxDx being the first healthcare ... marks a major achievement and a significant step ...
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
Breaking Medicine News(10 mins):Health News:Popular Publication on Behavioral Health Medications Now An App 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 4Health News:How to Turn Mid-life into the Good Life 2Health News:NABH Accreditation for Telerad RxDx – Whitefield. 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences International, ... primary efficacy endpoint in the Phase 3 clinical ... for the treatment of painful diabetic neuropathy did ... showed statistically significant improvement over placebo.  In addition, ... observed.  The results of this trial provide data ...
(Date:3/29/2015)... 2015  Three-month paliperidone palmitate, an investigational atypical ... placebo in patients with schizophrenia, according to a ... in the Journal of the American ... Results of the study served as the basis ... for three-month paliperidone palmitate injection to treat schizophrenia ...
(Date:3/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... issuance of an aggregate of 30,000 stock options to ... of 120,500 stock options to employees and consultants of ... years and will be exercisable for a period of ... stock option. About Covalon Covalon Technologies ...
Breaking Medicine Technology:BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Covalon Announces Issuance of Stock Options 2
Cached News: